CYPH
Cypherpunk Technologies Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.42
+6.61%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +36.6%
- EBIT
- +81.4%
- EPS
- +137.3%
- Free cash flow
- +55.0%
- Operating cash flow
- +51.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +140.4%
- EPS
- -86.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- +45.4%
- EBIT
- +47.8%
- Net income
- +107.1%
- EPS
- +104.0%
- Free cash flow
- +27.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026